Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 330 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR New on NCI’s Websites for December 2022 December 27, 2022 Cannabis, cannabinoids and cancer – the evidence so far September 1, 2021 Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer January 18, 2022 Can Getting a “Base Tan” Protect You From Sunburn and Skin... March 30, 2023 Load more HOT NEWS Woman Who Died For 27 Minutes Shares Haunting Message When Revived Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... The Appraisal – Does a charity have a role in biotech...
